Trial Profile
A Phase 1, Single-Center, Dose-Ranging, Multi-Treatment Study to Determine the Safety and Pharmacokinetics of Single Oral Dose Combinations of PF329 and Nafamostat Mesilate in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary) ; Nafamostat
- Indications Disseminated intravascular coagulation; Pain; Pancreatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Signature Therapeutics
- 06 Mar 2014 Status changed from not yet recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 28 Aug 2012 New trial record